Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xiaoer Jingxing Zhike Granules (Adult formulation) is an innovative Traditional Chinese Medicine (TCM) herbal granule formulation developed by Hunan Fangsheng Pharmaceutical for the treatment of respiratory conditions in adults. Originally approved for pediatric use, this specific formulation is being developed for adults to treat acute tracheobronchitis characterized by the TCM syndrome of wind-cold transforming to heat. The product contains a combination of herbal ingredients, including Schizonepeta (*Jingjie*), *Ardisia japonica* (*Aidicha*), and honey-processed *Ephedra* (*Mimahuang*). Its therapeutic mechanism involves dispersing wind and cold, ventilating the lungs, clearing heat, and relieving cough. Clinical trials have demonstrated its efficacy in improving symptoms such as cough, phlegm, and sore throat, and the drug is currently in the late stages of regulatory filing for the adult population.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Xiaoer Jingxing Zhike Granules (Adult formulation).